Advaxis, Inc. with TICKER NASDAQ:ADXS had its stock rating noted as ‘Coverage Initiated’ with the recommendation being set at ‘BUY’ today by analysts at MLV & Co. Advaxis, Inc. are listed in the Health Care sector within NASDAQ. MLV & Co have set a target price of 34 USD on its stock. This now indicates the analyst believes there is a potential upside of 80.7% from the opening price of 18.82 USD. Advaxis, Inc. NASDAQ:ADXS has a 50 day moving average of 17.38 USD and a 200 day moving average of 8.50 USD. The 52 week high share price is 24.48 USD while the 52 week low for the share price is 2.5 USD.
Advaxis, Inc. NASDAQ:ADXS is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm) – LLO immunotherapies. The Company develops immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under license from the University of Pennsylvania (Penn), that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The Company’s ADXS-HPV is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV)-associated cancers. ADXS-HPV is targeted for the treatment of cervical cancer, cervical intraepithelial neoplasia 2/3 (CIN 2/3) and head and Neck Cancer. ADXS-PSA is an Lm -LLO immunotherapy directed against prostate-specific antigen. ADXS-PSA is designed to target cells expressing PSA. ADXS-cHER2 is an Lm -LLO immunotherapy for HER2 overexpressing cancers.